Home › Research › Health systems and care delivery
Economic Cost of Alzheimer Disease in Israel
Michal Schnaider Beeri, Perla Werner, Zvi Adar, Michael Davidson, Shlomo Noy. Alzheimer Disease & Associated Disorders, 2002-04-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The objective of this prospective study was to evaluate the cost of Alzheimer disease (AD) in Israel. Seventy-one AD patients who lived in the community, 50 institutionalized AD patients, both AD groups' respective primary caregivers, and 50 healthy elderly subjects were interviewed. The interviews covered information about the number of caregivers' hours invested in caring for the patient and amount of expenditures such as in house paid help and payments for day care. The annual social cost of caring for a person with AD in Israel was approximately $17,000, whether the patient lived at home or in a nursing home, but the cost components differed in the two groups. For community-dwelling patients, 60% of the cost represented an imputed value of unpaid indirect care compared with 12% for institutionalized patients. Also, in both residences, the private cost was significantly higher than the public cost, i.e., more 75% of the services provided to patients were paid out of pocket. Cost of institutionalization was the major component of the social cost. The cost of the disease increased with functional and cognitive deterioration for the community-dwelling group only. With projected increases in the number of persons at risk for developing AD, the economic impact of the disease on future costs will be significant. Efforts to delay deterioration and, as a result, delay institutionalization seem crucial for cost containment.
What this study adds
Evidence grade: Low
This study estimated the economic cost of caring for people with Alzheimer's disease in Israel, finding that most services were paid out of pocket. It does not test any treatment, cure, or prevention, and it suggests that efforts to delay deterioration and institutionalization could affect future costs.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Beeri, M. S., Werner, P., Adar, Z., Davidson, M., & Noy, S. (2002). Economic Cost of Alzheimer Disease in Israel. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/00002093-200204000-00004
Vancouver
Beeri MS, Werner P, Adar Z, Davidson M, Noy S. Economic Cost of Alzheimer Disease in Israel. Alzheimer Disease & Associated Disorders. 2002. doi:10.1097/00002093-200204000-00004. PMID: 12040302.
BibTeX
@article{beeri2002-12040302,
author = {Beeri, Michal Schnaider and Werner, Perla and Adar, Zvi and Davidson, Michael and Noy, Shlomo},
title = {{Economic Cost of Alzheimer Disease in Israel}},
journal = {Alzheimer Disease \& Associated Disorders},
year = {2002},
doi = {10.1097/00002093-200204000-00004},
pmid = {12040302},
url = {https://doi.org/10.1097/00002093-200204000-00004}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- For community-dwelling patients, 60% of the cost represented an imputed value of unpaid indirect care compared with 12% for institutionalized patients.
- Also, in both residences, the private cost was significantly higher than the public cost, i.e., more 75% of the services provided to patients were paid out of pocket.
- With projected increases in the number of persons at risk for developing AD, the economic impact of the disease on future costs will be significant.
- Efforts to delay deterioration and, as a result, delay institutionalization seem crucial for cost containment.
Why it matters
This study estimated the economic cost of caring for people with Alzheimer's disease in Israel, finding that most services were paid out of pocket. It does not test any treatment, cure, or prevention, and it suggests that efforts to delay deterioration and institutionalization could affect future costs.
Study details
- Evidence strengthLow
How this study scored 33/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer Disease & Associated Disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 39 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 2 / 6 | Cited 1.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Shlomo Noy: h-index 26 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Icahn School of Medicine at Mount Sinai: institution h-index 1,331 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12040302) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.